Respiratory diseases
Conditions
Interventions
Control group:Sufentanil
Sponsors
Affiliated Hospital of Zunyi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients willing to undergo painless electronic bronchoscopy and sign the informed consent form; 2. Adult patients aged >=18 years, regardless of gender; 3. American Society of Anesthesiologists (ASA) classification I–II, Mallampati classification I–II; 4. Body Mass Index (BMI) 18.5 <= BMI < 24 kg/m^2; 5. No history of allergy to anesthetic drugs such as oxycodone and sufentanil.
Exclusion criteria
Exclusion criteria: 1. Preoperative severe organ dysfunction, such as liver or kidney dysfunction, or coagulation disorders; 2. Severe respiratory dysfunction (predicted MVV = 50% and predicted FEV1% < 50%); 3. Contraindications to nasopharyngeal airway use or expected difficult airway; 4. Patients with preoperative neuropsychiatric disorders or cognitive impairment; 5. Traumatic brain injury; 6. Cerebrospinal fluid rhinorrhea or otorrhea; 7. Nasal airway obstruction, nasal bone fracture, or obvious nasal septum deviation; 8. High risk of reflux and aspiration (pregnancy, full stomach, gastroesophageal reflux disease, hiatal hernia, or gastrointestinal obstruction); 9. Patients with acute or severe bronchial asthma; 10. Confirmed or suspected abuse or long-term use of narcotic sedatives and analgesics; 11. Refusal to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of respiratory depression;Adverse Event ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time;Mean Arterial Pressure;Heart Rate;Administered Dose;Airway Reactivity Score;Clinical Recovery Score;Quality of Recovery ;Norepinephrine level in blood; | — |
Countries
China
Contacts
Public ContactWang Haiying
Affiliated Hospital of Zunyi Medical University
Outcome results
None listed